Catalent (NYSE:CTLT) quickly rose 1% after a report that the contract drug manufacturer's $16.5 billion sale to Novo Holdings ...
Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...
In the U.S., the chorus of opposition against the proposed buyout continues to grow and now includes the CEOs of Roche and ...
Years of layoffs and alleged mismanagement have left employees “sick” of the pharmaceutical contract manufacturer Catalent, ...
Catalent Inc (CTLT) stock saw a modest uptick, ending the day at $63.24 which represents a slight increase of $1.00 or 1.61% from the prior close of $62.24. The stock opened at $62.5 and touched a low ...
Novo Holdings, the investment arm of the Novo Nordisk Foundation, has gained approval from the European Commission (EC) for ...
The European Commission on Friday unconditionally approved a controversial deal in which Novo Holdings, the parent company of ...
Catalent, Inc. ("Catalent," NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S ("Novo Holdings"), a global life sciences ...
As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have ...
The BIOSECURE Act, which would restrict drugmakers from using key Chinese contract manufacturers, was left out of a defense ...
Novo Holdings’ $16.5 billion takeover of US contract development and manufacturing organisation (CDMO) Catalent does not ...
SOMERSET, N.J. & COPENHAGEN, Denmark, December 14, 2024--(BUSINESS WIRE)--Catalent, Inc. ("Catalent," NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients ...